CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exo Therapeutics, Inc., a company pioneering the discovery and development of small molecules that bind to exosites, today announced the appointment of Laura Kiessling, PhD, to the company’s Scientific Advisory Board (SAB).
“Dr. Kiessling’s deep scientific rigor and expertise in chemical biology will be crucial in expanding the scope of our exosite research and understanding the complex interactions occurring on a molecular level,” said Michael Bruce, PhD, CEO of Exo Therapeutics. “Dr. Kiessling’s creativity and broad scientific expertise will be crucial as we continue to build our platform and drive new programs to the clinic. We very much look forward to working with her.”
“I am excited to work with the passionate Exo team and other SAB members to advance our understanding of exosites and work towards building the company’s science and pipeline to capture the tremendous potential of exosite-targeting medicines,” said Dr. Kiessling.
Laura Kiessling, PhD, is the Novartis Professor of Chemistry at the Massachusetts Institute of Technology (MIT) and runs the The Kiessling Group, a lab using chemical biology to elucidate the biological roles of carbohydrates, with a focus on learning new mechanistic concepts. Previously, she was a part of the faculty at the University of Wisconsin–Madison, where she became the Steenbock Professor of Chemistry, the Laurens Anderson Professor of Biochemistry, and the Director of the Keck Center for Chemical Genomics. Dr. Kiessling is a member of the American Academy of Arts & Sciences, the American Academy of Microbiology, the American Philosophical Society, and National Academy of Sciences. She is also the founding Editor-In-Chief of the journal ACS Chemical Biology. She is an author of over 140 peer-reviewed journal articles, an inventor on more than 28 US patents and the recipient of numerous honors and awards. She received an Sc.B. in chemistry at Massachusetts Institute of Technology where she performed undergraduate research in organic synthesis with Professor Bill Roush and a Ph.D. in chemistry at Yale University for her research with Stuart L. Schreiber.
Exo’s experienced, collaborative and dedicated team is passionate about pioneering exosite science to unlock breakthrough therapeutics. Dr. Kiessling joins Exo’s academic founders Alan Saghatelian, PhD, of the Salk Institute, and David Liu, PhD, of the Broad Institute and the Howard Hughes Medical Institute, as well as Dr. Charles Robert, MD, PhD, of the St. Jude Children’s Research Hospital, Professor Stuart Schreiber of the Broad Institute of MIT and Harvard, Professor Ben Cravatt, PhD, of the Scripps Research Institute, and Professor Ben Ebert, MD, PhD, of the Dana Farber Cancer Institute on Exo’s SAB.
About Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company's team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases. For more information, visit www.exo-therapeutics.com.
